Analysts See $-0.13 EPS for VIVUS, Inc. (VVUS)

February 15, 2018 - By Kurt Siggers

 Analysts See $ 0.13 EPS for VIVUS, Inc. (VVUS)
Investors sentiment decreased to 0.53 in 2017 Q3. Its down 0.74, from 1.27 in 2017Q2. It is negative, as 12 investors sold VIVUS, Inc. shares while 22 reduced holdings. 5 funds opened positions while 13 raised stakes. 32.65 million shares or 13.20% less from 37.61 million shares in 2017Q2 were reported.
Bridgeway Capital Mgmt invested in 637,200 shares. First Manhattan accumulated 27,000 shares. 90,121 are owned by Connor Clark And Lunn Investment Mgmt. Northern Trust Corporation stated it has 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Commerzbank Aktiengesellschaft Fi reported 0% in VIVUS, Inc. (NASDAQ:VVUS). Blackrock owns 2.30M shares. Jpmorgan Chase owns 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 2,500 shares. D E Shaw And stated it has 0% in VIVUS, Inc. (NASDAQ:VVUS). Schulhoff And has invested 0.01% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Bank Of America De holds 0% or 9,732 shares. Group Inc One Trading L P invested in 0% or 27,469 shares. Nine Chapters Mgmt Ltd Liability Co accumulated 92,800 shares. California-based Wells Fargo & Mn has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Sg Americas Llc holds 0% or 47,675 shares in its portfolio. Price T Rowe Assoc Md reported 51,000 shares or 0% of all its holdings.

Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.13 EPS on March, 14.They anticipate $0.67 EPS change or 124.07 % from last quarter’s $0.54 EPS. After having $-0.06 EPS previously, VIVUS, Inc.’s analysts see 116.67 % EPS growth. The stock 0.60% or $0 during the last trading session, reaching $0.47. It is down 7.14% since February 15, 2017 and is downtrending. It has underperformed by 23.84% the S&P500.

VIVUS, Inc. (NASDAQ:VVUS) Ratings Coverage

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. On Thursday, November 5 the stock rating was upgraded by WallachBeth Capital to “Buy”. On Friday, July 31 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Hold” rating by Zacks given on Wednesday, August 5.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $49.57 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It has a 1.38 P/E ratio. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: